Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | SELP | P16109 | 1/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.38 |
| ▸ | BCL6 | P41182 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 7/20 | 0.38 |
| ▸ | AXL | P30530 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | IDH2 | P48735 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4838872 | 0.92 | BCL6 (0.45) | MAPTMEN1LMNAKMT2ABCL6 | |
| SCHEMBL4836250 | 0.84 | BCL6 (0.46) | MAPTMEN1LMNAKMT2ABRD4 | |
| SCHEMBL4832385 | 0.84 | BCL6 (0.44) | MAPTMEN1LMNAKMT2ABCL6 | |
| SCHEMBL4840694 | 0.81 | BCL6 (0.52) | MAPTMEN1LMNAKMT2ABRD4 | |
| SCHEMBL4832441 | 0.81 | BCL6 (0.47) | MAPTMEN1LMNAKMT2ABRD4 | |
| SCHEMBL4840381 | 0.78 | BCL6 (0.45) | MAPTMEN1LMNAKMT2ABCL6 | |
| SCHEMBL4829068 | 0.78 | BCL6 (0.46) | MAPTMEN1LMNAKMT2ABCL6 | |
| SCHEMBL5435320 | 0.77 | BCL6 (0.49) | MAPTMEN1LMNAKMT2ABRD4 | |
| SCHEMBL4837087 | 0.76 | BCL6 (0.42) | LMNABCL6AXLAPOBEC3AAPOBEC3G | |
| SCHEMBL5032222 | 0.76 | BCL6 (0.57) | MAPTMEN1LMNAKMT2ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20040209882-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209882-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | MAPT 3539/4885MEN1 4761/4885LMNA 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.